Are overweight and obesity risk factors for cardiotoxicity from anthracyclines and trastuzumab in breast cancer patients?
Overweight and obesity increase the risk of cardiotoxicity in breast cancer patients receiving anthracyclines and trastuzumab.
Our findings in a largely unadjusted analysis suggest that overweight and obesity are risk factors for cardiotoxicity from anthracyclines and sequential anthracyclines and trastuzumab.
Guénancia et al. (Tue,) studied this question.